<DOC>
	<DOCNO>NCT00505492</DOCNO>
	<brief_summary>Primary Objectives : 1 . To test whether addition chemotherapy radiotherapy improve progression-free survival patient stage I , II IIIa malignant mixed mesodermal tumor ( MMMT ) uterus . 2 . To determine acute late toxicity profile associate treatment regimen . 3 . To describe effect treatment regimen patient 's quality life .</brief_summary>
	<brief_title>Malignant Mixed Mesodermal Tumor ( MMMT ) - Early Stage With Postoperative XRT/Chemotherapy</brief_title>
	<detailed_description>Patients study operation remove uterus , tube , ovary biopsy omentum lymph node enter study . Before treatment start , patient chest x-ray , compute tomography ( CT ) scan , blood test , physical exam . Patients history hearing loss hear test . Within 8 week surgery , patient receive 5 week combination radiation therapy cisplatin chemotherapy . Radiation cisplatin give Day 1 day 2 week follow 4 day radiation alone . An additional dose radiation , direct surface vagina , give either last week ( Week 5 ) treatment radiation cisplatin chemotherapy finish . Three five week radiation therapy cisplatin chemotherapy finish , patient receive additional chemotherapy . Carboplatin paclitaxel give every 28 day 4 cycle . All chemotherapy give vein catheter ( tube ) . Patients take study disease get bad intolerable side effect occur . Patients see one month last cycle chemotherapy , every 3-4 month 2 year . At visit , patient blood test physical exam . Computed tomography ( CT ) scan order suspected disease come back . All patient follow maximum 2 year therapy complete . This investigational study . Cisplatin , Carboplatin Paclitaxel FDA approve commercially available . A total 49 patient take part study . Up 25 patient may enrol M. D. Anderson Cancer Center Houston , 12 patient enrol MD Anderson Cancer Center , Orlando , 12 patient enrol University Texas Medical Branch Galveston .</detailed_description>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Mixed Tumor , Mesodermal</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients histologically confirm malignant mixed mesodermal ( MMMT ) confine pelvis ( Stage IB , IC , IIA , IIB , IIIA ) . Patients undergone total abdominal hysterectomy , vaginal hysterectomy laparoscopic assist vaginal hysterectomy bilateral salpinooophorectomy ( minimal surgical staging , include omental biopsy lymph node sample ) within 8 week study entry . No known metastatic extrauterine metastasis , know gross residual disease distant metastasis . Women racial ethnic group eligible . Zubrod performance status &lt; /= 2 . Adequate bone marrow , renal hepatic function : Hgb &gt; 10 gm/dl , ANC &gt; 1.5/mm3 , Platelets &gt; 100,000/mcl , Creatinine &lt; 1.5 mg/ % , Bilirubin &lt; 2.5 mg/dl , SGPT &lt; 2* ULN , BUN &lt; 1.5* ULN . No prior chemotherapy radiation therapy diagnosis . Estimated life expectancy 12 week great . Must sign institutionally approve informed consent . Previously treat malignant mixed mesodermal ( MMMT ) either chemotherapy radiotherapy ( XRT ) / Patients gross residual disease , suspect extrapelvic extrauterine disease distant metastatic disease ( Stage IIIB , IIIC IV ) . History malignancy , exception nonmelanomatous skin cancer , unless complete remission therapy disease minimum 5 year . Patients Zubrod performance status 3 great . Patients active systemic infection . Patients serious intercurrent medical illness . Patients recent ( within 6 month ) history cardiac dysrhythmia , congestive heart failure , unstable angina myocardial infarction .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Malignant Mixed Mesodermal Tumor</keyword>
	<keyword>MMMT</keyword>
	<keyword>Uterine Neoplasms</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Taxol</keyword>
</DOC>